Aldehyde-Terminated Multi-Arm PEG Hydrogel for Rapid Gelation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing medical hydrogels based on PEG derivatives suffer from poor long-term stability in aqueous solutions and slow gelation rates, limiting their practical applications in biomedical fields.
Innovation Solution
A medical hydrogel formed by in-situ crosslinking aldehyde-terminated multi-arm star polyethylene glycol with a polyamino compound using stable chemical bonds such as ether, amide, urethane, or urea bonds, allowing for controlled gelation and improved stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If succinimidyl ester-terminated PEG material is used for hydrogel formation, then rapid gelation is achieved, but long-term stability in aqueous solution deteriorates due to easy hydrolysis
Solution Approach 1:
The patent changes the chemical parameter of the bonding group from succinimidyl ester to hydrazone. This parameter change maintains the rapid gelation capability while dramatically improving long-term stability in aqueous solutions by reducing susceptibility to hydrolysis.
Solution Approach 2:
The patent creates a composite hydrogel system combining PEG derivatives with aldehyde groups and polyamino compounds containing hydrazone bonds. This composite structure leverages the advantages of both components to achieve rapid gelation and enhanced stability.
2Productivity
If aldehyde-terminated hyperbranched polymer HP-PEG-CHO is used with polyamino compound, then gelation is achieved through Schiff base formation, but long-term stability deteriorates due to ester bond hydrolysis
Solution Approach 1:
The patent modifies the bonding group parameter from ester bonds to hydrazone bonds in the PEG derivative structure. This change preserves gelation capability while eliminating the hydrolysis vulnerability of ester bonds, thereby improving long-term stability.
3Reliability
If conventional PEG derivatives are used for medical hydrogel, then biocompatibility is maintained, but gelation rate deteriorates due to slow crosslinking reaction
Solution Approach 1:
The patent introduces hydrazone bonding groups into the PEG derivative structure, which significantly accelerates the crosslinking reaction rate while maintaining the biocompatibility characteristics of PEG-based materials.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hydrogel exhibits rapid gelation and maintains stability over extended periods, enhancing its applicability in postoperative tissue closure, anti-leakage, tissue repair, and drug delivery.
Implementation Method 1
The aldehyde group and the amino group react with each other to generate a Schiff base for crosslinking
Implementation Method 2
Under external stimuli (changes in temperature, temperature/pH, etc.), the injectable hydrogel presents a phase transition between sol and gel
Data Source
AI summary
The present disclosure discloses a medical hydrogel, formed by in-situ crosslinking an aldehyde-terminated multi-arm star polyethylene glycol and a polyamino compound, wherein the aldehyde group and the multi-arm star polyethylene glycol are linked by a chemical bond such as an ether bond, an amide bond, a urethane bond, an imine bond, or a urea bond. In the present disclosure, the aldehyde group at the end of the multi-arm polyethylene glycol reacts with the amino group in the polyamino compound to produce Schiff base for crosslinking, so that the medical injectable gel is formed. The prepared gel has a short gelling time, a desired gel burst strength, and a good stability in an aqueous solution, and therefore has greater application value than existing medical gels.